Free Trial
NASDAQ:APRE

Aprea Therapeutics Q2 2025 Earnings Report

Aprea Therapeutics logo
$1.44 +0.02 (+1.75%)
Closing price 09/25/2025 03:58 PM Eastern
Extended Trading
$1.39 -0.05 (-3.72%)
As of 09/25/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.77
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Aprea Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aprea Therapeutics Earnings Headlines

New Buy Alert: Should you put $1,000 into Oracle (ORCL) now?
Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle the "New Nvidia." But is Oracle really the #1 AI stock you should buy today?tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction.

Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions.

Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.

View Aprea Therapeutics Profile

More Earnings Resources from MarketBeat